1058741-91-5 Usage
Uses
Used in Pharmaceutical Industry:
C5H2Cl3NO2S is used as a chemical intermediate for the synthesis of various pharmaceuticals due to its reactive nature and the presence of multiple functional groups that can be further modified in chemical reactions. Its strong electrophilic character allows it to participate in a wide range of reactions, facilitating the creation of diverse drug molecules.
Used in Organic Synthesis:
In the field of organic synthesis, C5H2Cl3NO2S serves as a key building block for the production of other organic compounds. Its unique structure with halogens and a nitro group provides opportunities for various synthetic pathways, making it a useful precursor in the development of new chemical entities with potential applications in different industries.
Used in Chemical Research:
C5H2Cl3NO2S is also utilized in chemical research as a model compound to study the reactivity and properties of halogenated and nitro-substituted aromatic systems. Understanding its behavior in different reaction conditions can provide insights into the design of new synthetic methods and the development of novel compounds with specific properties.
Check Digit Verification of cas no
The CAS Registry Mumber 1058741-91-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,8,7,4 and 1 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1058741-91:
(9*1)+(8*0)+(7*5)+(6*8)+(5*7)+(4*4)+(3*1)+(2*9)+(1*1)=165
165 % 10 = 5
So 1058741-91-5 is a valid CAS Registry Number.
1058741-91-5Relevant articles and documents
NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS
-
Page/Page column 106, (2008/12/07)
The present invention relates to substituted arylsulphonylglycines of general formula (I) wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof, which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1 ), and their use as pharmaceutical compositions.
